Ablative Radiation Therapy to Restrain Everything Safely Treatable (ARREST): A Phase 1 Study of Stereotactic Ablative Radiation Therapy for Polymetastatic Disease
Timothy K. Nguyen(Western University), Glenn Bauman(Thomas Jefferson University Hospital), Andrew Warner(Western University), Vikram Velker(Western University), Abhirami Hallock(Niagara Health System), Rohann Correa(London Health Sciences Centre), Pencilla Lang(London Health Sciences Centre), Melissa O’Neil(Western University), Michael Lock(London Health Sciences Centre), Sherif Ramadan(Western University), David A. Palma(Western University), Xiaotao Qu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Mark T. Corkum(Ottawa Hospital), A Celiński(Western University), Hatim Fakir(Western University)
Cited by 18
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k